CBFB mutations as a predictive biomarker of endocrine therapy benefit in hormone receptor–positive (HR+) breast cancer: Discovery and validation in 3,799 patients.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Adar Yaacov, Albert Grinshpun
Institutions: Shaare Zedek Medical Center, Bikur Cholim Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162537474
Cites:
Cited by:
Related to: